Investing in Johnson & Johnson
Johnson & Johnson has been a part of people's lives for more than 120 years and a valuable part of their investments for more than 60 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944.
During our history, we have built the most comprehensive base of health care businesses in the world, generating more than 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets.
Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 76 consecutive years of sales increases; 25 consecutive years of adjusted earnings increases; and 47 consecutive years of dividend increases. Over the last 10 years, Johnson & Johnson stock generated a 5.6 percent total return for investors compared to a -1.4 percent total return for the S&P 500.1
Our consumer products, pharmaceuticals, medical devices and diagnostics play a role in helping millions of people be well and stay well every day. We remain committed to improving the health and well-being of people everywhere, profitably growing our businesses, and enhancing the value we can bring to our shareholders.
E-Delivery of Annual Meeting and Proxy Materials
Johnson & Johnson is dedicated to improving the health and well-being of people everywhere. To fulfill this goal, we must protect the environments in which we work and live. A healthy planet and a healthy community go hand in hand. With this in mind, we now offer electronic versions of all of our company publications like the Annual Report.
|
Click here for the on-line Annual Report |
You can do your part as well. By reducing the amount of printed shareholder materials you receive, you can help protect the environment while quickly receiving important shareholder documents. In addition, reducing the printing and mailing costs associated with more traditional delivery methods allows us to control expenses in the interest of delivering more value for all our shareholders.
Registered Johnson & Johnson shareholders can sign up for electronic delivery of our reports and publications. Please go to www.computershare-na.com/green or contact our transfer agent, Computershare, at 1-800-328-9033.
Beneficial (owned through a broker/bank) Johnson & Johnson shareholders can register for on-line delivery of materials by clicking here and following the easy directions to your account.
Click here to see other financial documents and publications that can be electronically downloaded.
Investor News
September 2, 2010
Long Term Data Presented at ESC 2010 Shed Further Light on the Benefit of the CYPHER(R) Sirolimus Drug-Eluting Stent Compared to the ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
August 31, 2010
Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
August 31, 2010
CORDIS announces results of ten-year CYPHER® Sirolimus-eluting coronary stent follow-up
Investor Communications
Johnson & Johnson Comments on Mini-Tender Offer by TRC Capital Corporation
Financial Quick Links
Q2 2010 Earnings Announcement 
Q2 2010 Sales of Key Products/Franchises
5 Year Financial Review
1. Data source - Bloomberg
